RDS抗成瘾建模研究总结文档：注释书目
Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
作者信息
Blum Kenneth, Baron David, McLaughlin Thomas, Thanos Panayotis K, Dennen Catherine, Ceccanti Mauro, Braverman Eric R, Sharafshah Alireza, Lewandrowski Kai-Uwe, Giordano John, Badgaiyan Rajendra D
机构信息
Center for Sports and Mental Health, Western University Health Sciences, Pomona, CA, USA.
The Kenneth Blum Behavioral and Neurogenetic Institute, LLC., Austin, TX, USA.
出版信息
J Addict Psychiatry. 2024 Apr 5;8(1):1-33.
Abstract
Annotated bibliography of genetic addiction risk severity (GARS) publications, pro-dopamine regulation in nutraceuticals (KB220 nutraceutical variants), and policy documents. Further research is required to encourage the field to consider "Reward Deficiency Syndrome (RDS) Anti-addiction Modeling" which involves early risk identification by means of genetic assessment similar to GARS, followed by induction of dopamine homeostasis by means of genetically guided pro-dopamine regulation similar to KB220. These results suggest that genetically based treatments may be a missing piece in the treatment of substance use disorder (SUD).
摘要
关于遗传成瘾风险严重程度（GARS）出版物、营养保健品中多巴胺调节（KB220营养保健品变体）及政策文件的注释书目。需要进一步研究以促使该领域考虑“奖励缺乏综合征（RDS）抗成瘾模型”，该模型涉及通过类似于GARS的基因评估进行早期风险识别，随后通过类似于KB220的基因引导多巴胺调节来诱导多巴胺稳态。这些结果表明基于基因的治疗可能是物质使用障碍（SUD）治疗中缺失的一环。
相似文献
1
Summary Document Research on RDS Anti-addiction Modeling: Annotated Bibliography.
J Addict Psychiatry. 2024 Apr 5;8(1):1-33.
2
Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
CPQ Neurol Psychol. 2018;1(2). Epub 2018 Dec 4.
3
A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing "Precision Behavioral Management".
Psychol Res Behav Manag. 2021 Dec 17;14:2115-2134. doi: 10.2147/PRBM.S292958. eCollection 2021.
4
Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
J Syst Integr Neurosci. 2020 Aug;6(2). doi: 10.15761/JSIN.1000221. Epub 2019 Dec 19.
5
The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
Curr Pharm Biotechnol. 2023 Apr 27. doi: 10.2174/1389201024666230427111117.
6
A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
J Pers Med. 2021 Mar 16;11(3):212. doi: 10.3390/jpm11030212.
7
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry.
J Neurol Sci. 2023 Oct 15;453:120809. doi: 10.1016/j.jns.2023.120809. Epub 2023 Sep 23.
8
The Benefits of Genetic Addiction Risk Score (GARS) Testing in Substance Use Disorder (SUD).
Int J Genom Data Min. 2018;2018(1). doi: 10.29014/IJGD-115.000015. Epub 2018 Jan 15.
9
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
J Pers Med. 2022 Feb 21;12(2):321. doi: 10.3390/jpm12020321.
10
Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Int J Environ Res Public Health. 2021 Nov 2;18(21):11529. doi: 10.3390/ijerph182111529.
引用本文的文献
1
A GWAS Meta-meta-analysis and In-depth Silico Pharmacogenomic Investigations in Identification of APOE and Other Genes Associated with Pain, Anti-inflammatory, and Immunomodulating Agents in Opioid Use Disorder (OUD) Derived from 14.91 M Subjects.
Cell Mol Neurobiol. 2025 Jul 31;45(1):76. doi: 10.1007/s10571-025-01587-5.
2
Utilization of a precision medicine genetic and psychosocial approach in outcome assessment of bariatric weight loss surgery: a narrative review.
Front Public Health. 2025 May 1;13:1516122. doi: 10.3389/fpubh.2025.1516122. eCollection 2025.
3
Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case Series.
Psychol Res Behav Manag. 2025 Feb 1;18:225-240. doi: 10.2147/PRBM.S482960. eCollection 2025.
4
Response to the SAMHSA Clinical Advisory: Considerations for Genetic Testing in the Assessment of Substance Use Disorder Risk.
Subst Abuse Rehabil. 2025 Jan 26;16:23-26. doi: 10.2147/SAR.S514931. eCollection 2025.
5
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy.
J Addict Psychiatry. 2024;8(1):50-95. Epub 2024 Jun 20.
6
Addictive Behavior and Evolutionary Adaptation: Mitigated through Genetic Addiction Risk Severity Early Identification and Awareness Integration Theory.
Med Res Arch. 2024 Aug;12(8). doi: 10.18103/mra.v12i8.5702. Epub 2024 Aug 30.
7
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies.
Open J Immunol. 2024 Sep;14(3):60-86. doi: 10.4236/oji.2024.143006.
8
Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy-A Case-Series.
J Pers Med. 2023 Feb 15;13(2):336. doi: 10.3390/jpm13020336.
9
How to Combat the Global Opioid Crisis.
CPQ Neurol Psychol. 2023;5(4). Epub 2023 Jan 23.
10
Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of "Dopamine Homeostasis".
Open J Immunol. 2022 Sep;12(3):65-75. doi: 10.4236/oji.2022.123004.
本文引用的文献
1
The First Exploratory Personalized Medicine Approach to Improve Bariatric Surgery Outcomes Utilizing Psychosocial and Genetic Risk Assessments: Encouraging Clinical Research.
J Pers Med. 2023 Jul 20;13(7):1164. doi: 10.3390/jpm13071164.
2
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects.
J Pers Med. 2022 Aug 26;12(9):1385. doi: 10.3390/jpm12091385.
3
Preaddiction-A Missing Concept for Treating Substance Use Disorders.
JAMA Psychiatry. 2022 Aug 1;79(8):749-751. doi: 10.1001/jamapsychiatry.2022.1652.
4
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation.
J Pers Med. 2022 Jun 20;12(6):1009. doi: 10.3390/jpm12061009.
5
Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
Int J Environ Res Public Health. 2022 May 24;19(11):6395. doi: 10.3390/ijerph19116395.
6
FOXN3 and GDNF Polymorphisms as Common Genetic Factors of Substance Use and Addictive Behaviors.
J Pers Med. 2022 Apr 26;12(5):690. doi: 10.3390/jpm12050690.
7
Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".
Int J Environ Res Public Health. 2022 Apr 30;19(9):5480. doi: 10.3390/ijerph19095480.
8
Frequency of the Dopamine Receptor D3 (rs6280) vs. Opioid Receptor µ1 (rs1799971) Polymorphic Risk Alleles in Patients with Opioid Use Disorder: A Preponderance of Dopaminergic Mechanisms?
Biomedicines. 2022 Apr 7;10(4):870. doi: 10.3390/biomedicines10040870.
9
Overcoming reward deficiency syndrome by the induction of "dopamine homeostasis" instead of opioids for addiction: illusion or reality?
J Osteopath Med. 2022 Apr 12;122(7):333-337. doi: 10.1515/jom-2021-0026.
10
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
J Pers Med. 2022 Feb 21;12(2):321. doi: 10.3390/jpm12020321.
Zotero 插件